With the Supreme Court’s pending decision in Sandoz v. Amgen, the interpretation of the patent dance provisions of the BPCIA has been a hot topic here on the blog. For an in-depth analysis of patent dance strategies employed by biosimilar applicants to date, check out this article in Bloomberg’s Life Sciences Law & Industry Report written by BMW editors Alexandra Valenti, Alexandra Lu, Elaine Blais, and Rob Cerwinski.
![](https://www.bigmoleculewatch.com/wp-content/uploads/sites/2/2015/06/174260390_250x170.jpg)